Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer von Socinski, Mark A., Waller, Cornelius F., Idris, Tazeen, Bondarenko, Igor, Luft, Alexander, Beckmann, Katrin, Vishweswaramurthy, Ashwini, Loganathan, Subramanian, Donnelly, Charles, Hummel, Matthew A., Shapiro, Roxann, Woods, Melody, Rao, Anita, Nayak, Vivek G, Ranganna, Gopinath, Barve, Abhijit

Volltext

741-P: Efficacy and Safety of MYL-1601D (Mylan's Insulin Aspart) Compared with Novolog (Novo Nordisk's Insulin Aspart) in Patients with Type 1 Diabetes (T1DM) after 24 Weeks von RAITER, YARON, BLEVINS, THOMAS, SUN, BIN, DONNELLY, CHARLES M., RAO, ANITA U., SHAPIRO, ROXANN, VASHISHTA, LAXMIKANT, RANGANNA, GOPINATH, CHULLIKANA, ANOOP, BARVE, ABHIJIT

Volltext

Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog®) in Patients with Type 1 Diabetes After 24 Weeks: A... von Blevins, Thomas C., Raiter, Yaron, Sun, Bin, Donnelly, Charles, Shapiro, Roxann, Chullikana, Anoop, Rao, Anita, Vashishta, Laxmikant, Ranganna, Gopinath, Barve, Abhijit

Volltext

Showing What People Can and Cannot Do: Human Capacity and Limitations Demonstrations von Shapiro, Ronald G., White, Royce M., Brown, Megan L., Adams, Roxann E. P.

Volltext